Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MediPharm Labs's Enterprise Value is €15.30 Mil.
MediPharm Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-3.04 Mil. Therefore, MediPharm Labs's EV-to-EBIT ratio for today is -5.03.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, MediPharm Labs's Enterprise Value is €15.30 Mil.
MediPharm Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-2.06 Mil. Therefore, MediPharm Labs's EV-to-EBITDA ratio for today is -7.42.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, MediPharm Labs's Enterprise Value is €15.30 Mil.
MediPharm Labs's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €25.73 Mil. Therefore, MediPharm Labs's EV-to-Revenue ratio for today is 0.59.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, MediPharm Labs's Enterprise Value is €15.30 Mil.
MediPharm Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was €-0.66 Mil. Therefore, MediPharm Labs's EV-to-FCF ratio for today is -23.36.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
MediPharm Labs (STU:MLZ) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.04 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.06 Mil.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €25.73 Mil.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.62 Mil.
MediPharm Labs's current Enterprise Value is €15.30 Mil.
MediPharm Labs's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.66 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs Enterprise Value Related Terms
MediPharm Labs Enterprise Value Historical Data
* Premium members only.
The historical data trend for MediPharm Labs's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediPharm Labs Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Enterprise Value distribution charts can be found below:
* The bar in red indicates where MediPharm Labs's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
MediPharm Labs's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediPharm Labs (STU:MLZ) has a Enterprise Value of €15.30 Mil as of Aug. 28, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on MediPharm Labs and its competitors.
Is MediPharm Labs' Enterprise Value too high?
MediPharm Labs' current Enterprise Value is €15.30 Mil.
How does MediPharm Labs' Enterprise Value compare to ZTS?
MediPharm Labs' Enterprise Value of €15.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on MediPharm Labs and its competitors. MediPharm Labs's current Enterprise Value is €15.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediPharm Labs stock overvalued right now?
Based on GuruFocus' analysis, MediPharm Labs (STU:MLZ) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.05 — trading 13.8% above its estimated fair value. The current Enterprise Value is €15.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For MediPharm Labs (STU:MLZ), the current Enterprise Value is €15.30 Mil as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MediPharm Labs Corp and its subsidiaries produce cannabis, purified and pharmaceutical-like cannabis extracts, related derivative products, and cannabis-related medical information and services. Its operating subsidiaries hold cultivation, standard processing, and sale licences under the Cannabis Act (Canada), allowing the cultivation, sale, and distribution of cannabis oil, extracts, edibles, topicals, dried and fresh cannabis, and derivatives to authorized purchasers. Its subsidiary provides clinic services to Canadian patients requiring medical cannabis education and prescriptions. The company operates in one reportable segment, the production and sales of cannabis flower, and generates maximum revenue from Canada, with additional international sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MLZ has been successfully added to your 
